Introduction: Cardiac septal defects account for more than 50% of congenital heart
| INTRODUCTION
Congenital heart defects (CHDs) are the most common birth defects, with a prevalence of eight per 1000. 1 Among the birth defects, CHDs are the leading cause of infant mortality, comprising 28% of all major congenital anomalies. 2 Although a variety of subtypes of CHDs have been identified, the two most prevalent subtypes, ventricular septum defects (VSDs) and atrial septum defects (ASDs), account for more than half of the total CHD cases reported. 1, 3 These two CHDs are considered to be subtypes of cardiac septal defects.
Although cardiologists have made great efforts, the pathogenesis of CHDs is still not fully understood. Historically, CHDs are known as complex diseases that are a result of multiple factors, including
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environment influences and genetic factors. 4 However, in recent years, the importance of genetic factors has been emphasized, and more than 400 genes have been found to be associated with CHD. 5, 6 Notable examples include NKX2-5 (MIM* 600584), 7 
GATA4
(MIM* 600576), 8 TBX1 (MIM* 602054) 9 and ELN (MIM* 130160). 10 Cardiac ankyrin repeat protein (CARP), which is encoded by the ankyrin repeat domain 1 (ANKRD1, MIM* 609599) gene, is a nuclear transcriptional co-factor that regulates cardiac gene expression, 11 playing an important role in the myoplasm as a component of the cardiac sarcomere, where it is part of a multicomponent, titin-binding complex. 12, 13 Accumulating evidence suggests that mutation of ANKRD1 results in various cardiovascular disorders, including hypertrophic cardiomyopathy, dilated cardiomyopathy and total anomalous pulmonary venous return (TAPVR, MIM% 106700). [14] [15] [16] [17] [18] However, there is no evidence of a relationship between ANKRD1 and cardiac septal defects. In the present study, we provide evidence of a mutation of ANKRD1 that is associated with cardiac septal defect and modulates the function of ANKRD1/CARP. 
| MATERIALS AND METHODS

| Patient characteristics
| DNA extraction
Approximately 6.0 ml of peripheral blood was collected from each participant. DNA was extracted from peripheral blood lymphocytes using a Gentra Puregene blood kit (Qiagen, Santa Clara, CA, USA).
| Whole exome sequencing
Whole exome sequencing was performed in the proband, and her sister and parents, using the Sure Select Human All Exon V6 Kit Splicing variations that are no greater than 2 bp (± 1 or 2 bp) from the exon are reserved. Mutations that are predicted by dbscSNV to affect splicing are reserved (the filtering flowchart is shown in Figure 1 ).
| Sanger sequencing
After 
| Conservation analysis across species
The protein sequences with respect to ANKRD1 in 11 species, from Drosophila melanogaster to Homo sapiens, were aligned using ClustalX, version 1.81, 2.1 (http://www.clustal.org/clustal2).
| Plasmids and site-directed mutagenesis
The full-length wild-type (WT) cDNA of the human ANKRD1 gene was amplified by a polymerase chain reaction (PCR) using PrimeSTAR® HS DNA Polymerase (Takara, Liaoning, China) and specific primers. The PCR fragments were double digested with the endonucleases Xhol and BamHI (Thermo Fisher, Shanghai, China) and the digested product was fractionated by 1.5% agarose gel electrophoresis, then purified Sequences of primers used for plasmid construction are shown in the Supporting information, Table S1 .
| Dual luciferase report assay
HEK293 cells 13 
| Real-time PCR
The expression of WT or MUT ANKRD1 and endogenous ANF was detected by PCR in accordance with standard procedures. Quantitative real-time PCR was performed using the ABI PRISM® 7500
Sequence Detection System (Applied Biosystems) and SYBR Green qPCR SuperMix (Applied Biosystems/Invitrogen). Quantitative evaluation of target gene levels was carried out by comparing ΔC t values using 18S rRNA as an internal control. Sequences of the PCR primers are shown in the Supporting information, Table S2 .
| Statistical analysis
Statistical analysis was performed using SAS-PC, version 9.3 (SAS Institute, Inc., Cary, NC, USA). Data are expressed as the mean ± SD.
Comparisons between two groups were performed using the chisquared test. Statistical significance was determined by one-way analysis of variance and subsequent pairwise comparisons were performed. p < 0.05 was considered statistically significant.
FIGURE 1
Bioinformatics processing and filtering of variants from whole exome sequencing. The processing analysis was consistent with basic analysis and advanced analysis. The advanced analysis may be divided into three important parts: filtering of harmful mutation, filtering of family distribution and filtering of a gene and its phenotype 3 | RESULTS
| Clinical characteristics
The proband was a 1-year-old girl who was diagnosed with ostium secundum ASD (2. 
| Identification of ANKRD1 c.C560T:p.S187F as our candidate mutation
To identify genetic mutations that were associated with cardiac septal defects in this family, we performed whole exome sequencing analysis on four DNA samples, from members III-7 and III-8 (the parents), and FIGURE 2 A, Pedigree structure of a family with cardiac septal defects.III-4, IV-2: atrial septal defect; IV-3: atrial septal defect and ventricular septal defect; III-7: carrier; arrow: proband patient; ×: deceased. B, C, The mutant of p.S187F in ANKRD1 confirmed by Sanger sequencing. B, Wild-type (WT); c, mutant type (MUT); the arrow shows the site of p.S187F. D, Conservation of the ANKRD1 p.S187F site in different species. The block shows the site of p.S187F in different species. aa, aamino acid; -, absence of similar amino acids. E, Schematic diagram of ANKRD1 and the site of p.S187F. Aa, aamino acids; NLS, putative nuclear localization signature motif; NES, putative nuclear export signature motif; the arrow indicates the site of p.S187F
IV-2 and IV-3 (the proband and her sister). More than 22 000 indels, 167 000 single nucleotide polymorphisms (SNPs) and 10 copy number variations were found in each subject (see Supporting information, 
| The p.S187F site is conserved across species with different cardiac structures
To support the role of the p.S187F site in the ANKRD1 protein structure, we evaluated the evolutionary conservation of the surrounding sequence by cross-species alignment. The amino acid at the p.S187F site was conserved evolutionarily from Xenopus tropicalis To confirm these findings, we assessed the effect of WT or MUT ANKRD1 expression on endogenous ANF mRNA expression. The relative expression of ANF in both ANKRD1 groups showed a significant decrease; however, the decrease for the MUT group was greater than the decrease for the WT group (0.85 ± 0.05 versus 0.61 ± 0.04, p < 0.01) (Figure 3d ). These results confirm the suppressive effect of the p.S187F mutation on cardiac gene expression.
| The p.S187F mutation decreases the nuclear distribution of ANKRD1
Given that ANKRD1 functions as a transcriptional repressor, we reasoned that any change of intracellular distribution may result in regulatory dysfunction of associated signaling pathways. Therefore, we performed localization analysis of the p.S187F ANKRD1 mutant as a possible explanation for the change in repressor function.
HEK293 cells were transfected with WT ANKRD1 or MUT ANKRD1
fused with green fluorescent protein (GFP) and detected by confocal microscopy. In the normal control group, in which the empty pEGFP-C3 vector was transfected, both nuclei and cytoplasmic compartments showed fluorescence (Figure 4a-c) . Furthermore, for WT ANKRD1, the fluorescence was distributed more in the nucleus than in the cytoplasm ( Figure 4d-f) ; however, MUT ANKRD1 had an altered distribution, with higher concentrations in the cytoplasm around nuclei than in the nuclei per se (Figure 4g-i) . These results indicate the p.S187F mutation change the intracellular distribution of ANKRD1
and may consistent with the possibility that p.S187F mutation modulates ANKRD1 function by altering its nuclear localization.
| DISCUSSION
In the present study, a heterozygous missense variant of ANKRD1 c.
C560T:p.S187F was detected as a deleterious mutant by whole exome sequencing, and the mutant was found to be pathogenic by bioinformatics and functional prediction analyses. Furthermore, Sanger sequencing showed incomplete dominant heredity. Interestingly, the conservation of this mutant was not complete for all species:
in lower species without a cardiac septum structure, this site was not conserved but, in higher species with cardiac septum structure, it was highly conserved. 21 According to these observations, we speculate that the mutation is likely to have caused defects in cardiac septal development for affected family members, although the pattern of incomplete dominant heredity suggests that other factors may contribute to the presentation of the defect.
CARP, a cardiac-specific transcriptional repressor, consists of 319 amino acids, including a coiled-coil domain, two putative nuclear localization signature motifs, two PEST protein degradation sequences, one putative nuclear export signature motif and an ankyrin repeat domain consisting of five ankyrin repeats. 22 The mutant site of p.S187F was located after the second ANK repeats and in front of the potential nuclear export signal domain of the second ANK (Figure 2e ).
Accumulating studies show that mutation in this domain of the ANKRD1 protein may alter its interaction with Talin-1, FHL2 or Titin, which may be associated with cardiac defects, dilated cardiomyopathy, hypertrophic cardiomyopathy or total anomalous pulmonary venous return. 21, 23 Thus, this circumstantial evidence supports the possibility that the p.S187F mutant of ANKRD1 is involved in the pathogenesis of the cardiac septal defect.
As a multifunctional gene, ANKRD1 interacts with many structural proteins. Binding of ANKRD1 with myopalladin is essential for maintaining sarcomere structural integrity, and consistently, mutations
of ANKRD1, such as Pro52Ala, Thr123Met and Ile280Val, enhance its binding to myopalladin and are associated with hypertrophic ; it can interact with nuclear factor κ-light-chain-enhancer of activated B cells and produce an antiinflammatory function 24 ; and in cultured skeletal muscle cells, ANKRD1 acts as a positive transcriptional co-activator of p53, suggesting a regulatory role during development and stress response. 25 Furthermore, ANKRD1 can also bind to signaling molecules, such as FHL2, CASQ2 and PKCα, and mutation of ANKRD1 may lead to regulatory dysfunction of associated signal molecular pathways, which is highly associated with cardiomyopathy or heart failure. 21, 26 On the basis of the above studies, we speculate that the p.S187F mutant of ANKRD1 may modulate the interaction with one or more proteins that are involved in the expression of cardiac developmental genes.
To assess this possibility, we examined the ability of WT-and MUT-ANKRD1 proteins to modulate the expression of the cardiac gene ANF, which is known to be activated by NKX2.5. by Ishiguro et al. 28 However, Zou et al. 11 found ANKRD1 expression in the nuclei of rodent cultured cardiac cells, and several studies have demonstrated that ANKRD1 has a dual subcellular localization, where FIGURE 4 P.S187F mutation modulates the localization of exogenous ANKRD1 in HEK293 cells. HEK293 cells were transiently transfected with constructs overexpressing human wild-type ANKRD1 (WT, D to F) or mutant ANKRD1 (MUT, G to I) fused with GFP (green). Localization was visualized by confocal microscopy. pEGFP-C3 vector was used as the normal control (NC, A to C) and 4',6-diamidino-2-phenylindole was used for nuclei labeling (blue). The results are representative of three experiments it presents in the cytoplasm as a component of the cardiac sarcomere and also presents in the nucleus as a transcriptional regulator during cardiomyogenesis. 13, 22, 23, 29 In the study, WT ANKRD1 was detected in both the cytoplasm and nucleus, although the nucleus showed a stronger positive signal of GFP; however, in the mutant group, ANKRD1 was more concentrated in the cytoplasm, indicating that mutation leads to relatively low expression of ANKRD1 in the nucleus, and that altered distribution of the mutation might be associated with the regulatory dysfunction of p.S187F ANKRD1. Given the large number of interacting partners, it is possible that ANKRD1 may repress transcription by removing interacting transcriptional activators from the nucleus or by modulating the function of a cytoplasmic signaling protein, although these possibilities would need to be confirmed in subsequent studies.
In conclusion, the p.S187F mutation may enhance the repressor function of ANKRD1, leading to abnormal cardiac gene expression and an association with cardiac septal defect. Additional functional studies to support the role of ANKRD1 in the pathogenesis of cardiac septal defects may further confirm these findings, including studies that involve both ANKRD1 overexpressing transgenic animals and screening of ANKRD1 mutations in additional cardiac septal defect patients.
